Gamida Cell Secures Funding for Allogeneic Stem Cell Transplant Commercialization
In a recent announcement, Gamida Cell Ltd disclosed plans to receive a significant injection of capital from Highbridge Capital Management to support the commercialization of their allogeneic stem cell transplant, Omisirge. This move comes as the company’s cash and cash equivalents grew by 16.79% in the third quarter of 2023, while current liabilities decreased, resulting in an improved quick ratio of 3.06.
On a trailing twelve-month basis, Gamida Cell’s cash and cash equivalents increased by 3.03% year on year in the third quarter of 2023, leading to a rise in their trailing twelve-month quick ratio to 2.58. Despite this improvement, the quick ratio remained below Gamida Cell’s 12-month average.
This strategic partnership with Highbridge Capital Management signals a positive step forward in Gamida Cell’s restructuring process, ensuring a solid financial foundation for the commercialization of Omisirge. The infusion of new capital is expected to accelerate the growth and development of their allogeneic stem cell transplant technology, positioning Gamida Cell for future success in the healthcare industry.
Comments